Several large-scale cardiovascular outcome trials (including LEADER, SUSTAIN-6, and REWIND) have shown that certain GLP-1 receptor agonists liraglutide, semaglutide, and dulaglutide reduce the risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death in people with established cardiovascular disease or multiple cardiovascular risk factors
Myofascial pain syndrome and its suggested role in the pathogenesis and treatment of fibromyalgia syndrome
Methods We did a systematic review and meta-regression analysis of case-control studies, including studies nested in cohorts, of the association between concentrations of IGF-I and IGFBP-3 and prostate, colorectal, premenopausal and postmenopausal breast, and lung cancer
While the mechanism is likely multifactorial, including weight loss, improved glycaemic control and reduced systemic inflammation, these data suggest a class effect that may be particularly valuable for PsA, where metabolic and cardiovascular risk are major drivers of long-term morbidity
